Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Janone Inc (JAN)

Janone Inc (JAN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 20,017
  • Shares Outstanding, K 8,976
  • Annual Sales, $ 0 K
  • Annual Income, $ -7,810 K
  • 60-Month Beta 2.16
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade JAN with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.38
  • Most Recent Earnings $-0.34 on 05/03/24
  • Next Earnings Date 08/20/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.72 +29.65%
on 07/08/24
2.67 -16.48%
on 06/21/24
-0.34 (-13.23%)
since 06/12/24
3-Month
1.72 +29.65%
on 07/08/24
5.26 -57.60%
on 04/29/24
-0.72 (-24.41%)
since 04/12/24
52-Week
0.22 +911.80%
on 10/10/23
5.26 -57.60%
on 04/29/24
+1.25 (+126.40%)
since 07/12/23

Most Recent Stories

More News
JANONE CONFIRMS NAME CHANGE TO ALT5 SIGMA CORPORATION AND NEW TICKER SYMBOL TO ALTS

/CNW/ -- JanOne Inc. (Nasdaq: JAN), a multidisciplinary organization with a focus on fintech and healthcare, confirmed today that, as of market open on Monday,...

JAN : 2.23 (+4.21%)
JanOne Announces Plan to Enhance Stockholder Value Through Strategic Realignment

/CNW/ -- JanOne Inc. (Nasdaq: JAN), a multidisciplinary organization with a focus on fintech and healthcare, has announced plans to enhance stockholder value...

JAN : 2.23 (+4.21%)
JanOne Appoints Vay Tham as its Chief Revenue Officer and President of its Fintech Subsidiary, ALT5 Sigma

/CNW/ -- JanOne Inc. (Nasdaq: JAN), a multidisciplinary organization with a focus on healthcare and fintech, is pleased to announce that it has appointed Mr....

JAN : 2.23 (+4.21%)
ALT5 SIGMA, A JANONE COMPANY, ADDS PREPAID VISA®️ CARD INTEGRATION TO ALT5 SETTLEMENT PLATFORM

/CNW/ -- JanOne Inc. (Nasdaq: JAN), a multidisciplinary organization with a focus on healthcare and fintech, announced today that its wholly-owned subsidiary,...

V : 265.45 (unch)
JAN : 2.23 (+4.21%)
JanOne's Subsidiary, Alt5, Reports 91% year over year increase in Transaction Volume to US $289 million for April and May 2024

/CNW/ -- JanOne Inc. (Nasdaq: JAN), a multidisciplinary organization with a focus on healthcare and fintech, released today its wholly-owned subsidiary, ALT5...

JAN : 2.23 (+4.21%)
JanOne to Present at the Dawson James 8th Annual Investment Conference

/PRNewswire/ -- JanOne (Nasdaq: JAN), the biopharmaceutical company focused on developing non-addicting painkillers and novel treatments for the causes of...

JAN : 2.23 (+4.21%)
JanOne to Present In Person and by Video at H.C. Wainwright's 25th Annual Global Investment Conference

/PRNewswire/ -- JanOne (Nasdaq: JAN), the biopharmaceutical company focused on developing non-addicting painkillers and novel treatments for the causes of...

JAN : 2.23 (+4.21%)
JanOne Earns US Patent for the Use of its Novel Formulation of Low-Dose Naltrexone, Jan123, to Treat Chronic Pain

/PRNewswire/ -- JanOne (Nasdaq: JAN), the visionary biotech company dedicated to discovering non-addictive treatments for pain, as well as causes of pain, has...

JAN : 2.23 (+4.21%)
JanOne Wins "Best Abstract" Award at the Ohio Society of Interventional Pain Physicians Annual Meeting

/PRNewswire/ -- JanOne (Nasdaq: JAN), the biopharmaceutical company focused on developing non-addicting painkillers and novel treatments for the causes of...

JAN : 2.23 (+4.21%)
JanOne Technologies Announces Closing of Registered Direct Offering Priced At-The-Market under Nasdaq Rules

/PRNewswire/ -- JanOne (Nasdaq: JAN) (the "Company"), a biopharmaceutical company specializing in developing non-addicting pain killers and treatments for...

JAN : 2.23 (+4.21%)

Business Summary

JanOne is focused on developing treatments for diseases that cause severe pain. By alleviating pain at the source, JanOne aims to reduce the need for opioid prescriptions to treat disease associated pain that can lead to opioid abuse. The company is also exploring solutions for non-addictive pain medications....

See More

Key Turning Points

3rd Resistance Point 2.58
2nd Resistance Point 2.48
1st Resistance Point 2.35
Last Price 2.23
1st Support Level 2.12
2nd Support Level 2.02
3rd Support Level 1.89

See More

52-Week High 5.26
Fibonacci 61.8% 3.33
Fibonacci 50% 2.74
Last Price 2.23
Fibonacci 38.2% 2.15
52-Week Low 0.22

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar